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Gypenoside (GP) is the major effective component of Gynostemma pentaphyllum
and has been shown to encompass a variety of pharmacological activities. In
this study, we investigated whether GP is able to protect cardiomyocytes against
injury myocardial ischemia–reperfusion (I/R) injury by using in vitro oxygen-glucose
deprivation–reoxygenation (OGD/R) H9c2 cell model and in vivo myocardial I/R rat
model. We found that GP pre-treatment alleviated the impairments on the cardiac
structure and function in I/R injured rats. Moreover, pre-treatment with GP significantly
inhibited IκB-α phosphorylation and nuclear factor (NF)-κB p65 subunit translocation
into nuclei. GP and the MAPK pathway inhibitors also reduced the phosphorylation of
ERK, JNK, and p38 in vitro. Specific inhibition of ERK, JNK, and p38 increased the
cell viability of OGD/R injured cells. Taken together, our data demonstrated that GP
protects cardiomyocytes against I/R injury by inhibiting NF-κB p65 activation via the
MAPK signaling pathway both in vitro and in vivo. These findings suggest that GP may
be a promising agent for the prevention or treatment of myocardial I/R injury.
Keywords: cardiomyocytes, gypenoside, I/R injury, MAPK, NF-κB
INTRODUCTION
As a predominant factor of heart injury, myocardial ischemia–reperfusion (I/R) is generally
characterized by the deficient supply of blood flow to the myocardium, which leads to dramatic
decrease in nutrients that are essential for energy generation. This disorder is always inevitable
in that generation of I/R injury is associated with procedures used to re-establish blood flow
to minimize heart damage due to severe myocardial ischemia (Kim et al., 2009; Ma et al.,
2014), and such procedures are necessary for current therapies for coronary heart disease. These
treatment modalities are effective in weakening acute myocardial ischemic injury and limiting
myocardial infarction size, but they will themselves induce further cardiomyocytes death during the
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reperfusion process, namely I/R injury (Braunwald and
Kloner, 1985; Piper et al., 1998; Yellon and Hausenloy, 2007).
Unfortunately, although technologies and agents against
myocardial disease are being rapidly developed, few effective
strategies for prevention of myocardial I/R injury are available.
Ischemia–reperfusion injury can induce cell death or
apoptosis, which is generally recognized to be initiated by
reactive oxygen species (ROS) along with calcium overload and
mitochondrial permeability transition (MPT) pore open (Wong
et al., 2012). Moreover, various cytokines and Toll-like receptors
are also released as part of the activation of the innate immune
response in I/R injury (Frantz et al., 2005). The expression
of ROS and innate immune factors leads to the downstream
regulation of nuclear factor kappa B (NF-κB). NF-κB is a nuclear
transcription factor regulating the immediate-early and stress
response genes which are stimulated during acute inflammatory
responses in various diseases, including ischemic pathology
(Frantz et al., 2007; Wang et al., 2007). Previous evidence
indicates the augmentation of NF-κB subunit p65 mediated
inflammatory response in liver I/R injury model (Ramachandran
et al., 2012). Several upstream pathways, such as MAPK and
PI3K/Akt-related signal transduction, regulate the activation of
NF-κB, i.e., phosphorylation of IκBα is initiated by PI3K/Akt
phosphorylation, leading to the activation of NF-κB (Dilshara
et al., 2014). NF-κB is also an important downstream target of
MAPK signaling transduction in inflammatory and immune
response (Baeuerle and Baltimore, 1996; Dai et al., 2011). It is
reported that p38 MAPK (p38), c-Jun NH(2)- terminal kinase
(JNK), and extracellular signal-regulated kinase (ERK) activation
may up-regulate NF-κB by phosphorylation of IKK-β (Huang,
2008; Yeh et al., 2011; Slomiany and Slomiany, 2013). Moreover,
p38 is also involved in the benzoquinone-mediated activation
of NF-κB (Stokes and Winn, 2013) and an ERK-RhoA-NF-κB
activation loop in breast cancer cells is also validated by Bist
et al. (2015). Regarding I/R injury, the modulation of NF-κB
by members of the mitogen-activated protein kinase (MAPK)
signal transduction pathway is also verified (Chung et al., 2012;
Himaya et al., 2012). Based on these studies, it is reasonable to
conceive members of MAPK pathway as potential therapeutic
targets for reducing cardiomyocytes loss due to myocardial I/R
injury.
Gynostemma pentaphyllum, also known as ‘Jiaogulan,’ is a
traditional medicine and herbal tea in Asian countries. The
agent has been long time used as a medicine against chronic
inflammation, hyperlipidemia, and liver diseases (Qin et al.,
2012). Gypenoside (GP) is the predominant component of
Gynostemma pentaphyllum and is capable of protecting tissues
against inflammatory, tumor, and oxidant (Zhang G. et al., 2011;
Zhang G.L. et al., 2011; Qin et al., 2012). Furthermore, therapeutic
effects of GP on chronic hepatic injury in rat models have been
reported (Zhang G.L. et al., 2011; Qin et al., 2012). However,
few studies have investigated the effects of GP on myocardial I/R
injury.
In the present study, the protective effects of GP against
I/R injury were investigated by using in vitro oxygen-glucose
deprivation–reoxygenation (OGD/R) H9c2 cell model and
in vivo myocardial I/R rat model.
MATERIALS AND METHODS
Materials
Gypenoside (purity > 99%) was purchased from Meilune
Biotech (Catal. No. MB6716, Dalian, China) and dissolved in
saline according to the manufacturer’s instruction. Based on the
monograph of Chinese Pharmacopoeia Commission (1995), GP
was obtained from the water extract of the aerial part of the
G. pentaphyllum using chromatography method. Supplementary
Figure S1 shows the general structure for dammarane-type
GPs (Aktan et al., 2003). Antibodies against NF-κB subunit
p65 was purchased from Boster (Catal. No. BA0610. China).
Antibodies against phosphorylated IκBα (p-IκBα), IκBα, p-ERK,
ERK, p-JNK, JNK, p-p38, and p38 were purchased from Beijing
Biosynthesis Biotechnology Co., LTD (Catal. No. bs-5515R, bs-
1287R, bs-1522R, bs-2637R, bs-1640R, bs-10562R, bs-5477R, bs-
0637R, Beijing, China). Antibody against β-actin was purchased
from Santa Cruz Biotechnology, Inc. (Catal. No. sc-47778, Santa
Cruz, CA, USA). MAPK pathway inhibitors U0126 (inhibitor
of MEK1/MEK2), SP600125 (inhibitor of JNK), and SB203580
(inhibitor of p38) were purchased from Sigma–Aldrich (St Louis,
MO, USA). All the material under current study is non-toxic
to animals and cell cultures, including not only GP, but also all
biologics and synthetics used for immunopharmacologic studies.
Animal and Cell Cultures
H9c2 rat cardiac cell line was obtained from American Type
Culture Collection (ATCC; Rockville, MD, USA) and incubated
with DMEM/F-12 medium [10% (v/v) fetal calf serum and 1%
(v/v) antibiotics mixture] in 95% air and 5% CO2 at 37◦C. Eight-
week-old male Wistar rats (weighing 240–260 g) were provided
by Experimental Animal Center of China Medical University.
Animals were raised at room temperature (20–25◦C) with a
constant humidity (55 ± 5%) with free access to food and water.
All animal experiments were conducted in the accordance with
the Institutional Animal Ethics Committee and Animal Care
Guidelines for the Care and Use of Laboratory of Animals of
Experimental Animal Center of China Medical University who
governed the use of the animals.
Cardiomyocytes I/R Injured Rat Models
Establishment
Myocardial I/R injury model was induced based on previous
study (Pfeffer et al., 1979) with some modifications. Briefly, the
rats were anesthetized with pentobarbital sodium (50 mg/kg i.p.)
before endotracheal intubation. After anesthesia, the animals
were placed in a supine position and a lateral thoracotomy
(1.5 cm incision between the third and fourth ribs) was
performed to expose the left anterior descending coronary
artery (LAD). A ligation using nylon suture was placed
around the LAD at 3–5 mm for 45 min followed by 3 h
of reperfusion. For rats in sham group, ddH2O was used
instead of GP and rats were underwent the same surgical
procedure without ligation. Ninety male Wistar rats were
selected and randomly divided into five groups (18 for each
group) and GP administration doses were employed according
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to study of Zhao et al. (2014) with some modifications
(Wang et al., 2010): (1) I/R group, rats underwent I/R injury
induction. (2) I/R + GPL group, rats were gavaged with
50 mg/kg body weight GP 1 h before model establishment. (3)
I/R + GPM group, dose of GP was adjusted to 100 mg/kg
body weight. (4) I/R + GPH group, dose of GP was adjusted to
200 mg/kg body weight. (5) Sham group. Of all the experimental
animals in each group, six rats were used for hemodynamics
parameters measurement and hematoxylin and eosin (H&E)
staining, six ones were used for TTC staining and lactate
dehydrogenase (LDH) and creatine kinase (CK) detection, and
the left six were used for EMSA, ELISA, and Western blotting
assay.
OGD/R H9c2 Cell Model
For OGD treatment, H9c2 cells at log-growth stage
(concentration adjusted to 5 × 104/mL) were cultured in
glucose-free DMEM medium in an atmosphere of 95% N2 and
5% CO2 at 37◦C for 4 h. For reoxygenation, OGD cells were
incubated with medium containing 4.5 mg/mL glucose and
normal oxygen (21%) for 24 h. Five different treatments were set
up and administration doses of GP were employed according
to studies of Zhu et al. (2012): (1) control group, normal H9c2
cells. (2) OGD/R group. (3) OGD/R + GPL group, cells were
incubated with 5 µM GP for 24 h before model establishment.
(4) OGD/R + GPM group, dose of GP was adjusted to 10 µM.
(5) OGD/R + GPH group, dose of GP was adjusted to 20 µM.
Each treatment was represented by three replicates.
In addition, in in vivo experiment, the expressions of p-ERK,
p-JNK, and p-p38 were all influenced by the treatment of GP.
Based on these results, another three treatments with H9c2 cells
were set up to reveal the possible mechanism involved in GP
inhibiting NF-κB activity and administration doses of MAPK
inhibitors on H9c2 was 10 µM according to previous studies
(Aggeli et al., 2006; Yin et al., 2013): (6) OGD/R+U0126, 10 µM
U0126 was added at the same time of GP administration. (7)
OGD/R + SP600125, 10 µM SP600125 was added at the same
time of GP administration. (8) OGD/R + SB203580, 10 µM
SB203580 was added at the same time of GP administration. Each
treatment was represented by three replicates.
Hemodynamics Parameter Measurement
At the end of I/R procedure, left ventricular end systolic
pressure (LVESP) and left ventricular end-diastolic pressure
(LVEDP) were monitored with six awake rats in each group
with a non-invasive blood pressure system (XBP 1000, Kent
Scientific, Torrington, CT, USA) according to the manufacturer’s
instruction. Briefly, the rats were fastened in a restrainer for a
long period for the acclimation to the device, which was judged
by the absence of struggling. The factional shortening (FS) was
calculated by assuming a spherical left ventricular geometry with
the algorithms of ultrasound system using Philips iE33 system
(Philips Ultrasound, Bothell, WA, USA). All the parameters were
represented by at least three replicates.
After the measurement of hemodynamics parameters, heart
tissues of rats in different treatments were harvested and
preserved in−80◦C for H&E staining, TTC staining, and further
analysis.
Histopathological Staining
Hematoxylin and Eosin staining with ischemic penumbra part
of heart tissue samples in each group was conducted for
the observation of the histological changes of tissue samples
in different groups according to the previous study (Mayer,
1896). The results were detected under a microscope at 200×
magnification. Then the whole left ventricle of the heart of each
sample was cut into five 2-mm transverse slices and the infarction
areas were determined using TTC method. Tissue samples were
incubated in 1% (TTC) in a 7.4 pH buffer for 10 min at 37◦C
to demarcate the infarction area: pale tissue was presumed to be
infarcted. The infarcted area percentage of different samples was
calculated using the Image-Pro Plus software.
ELISA and EMSA
The levels of LDH and CK in serum samples were determined
using ELISA assay kits (Catal. No. A032, A020-1, Nanjing
Jiancheng Bioengineering Institute, Nanjing, China) according to
the manufacturer’s instructions. The activities of NF-κB subunit
p65 in different groups were measured using ELISA Kit (Catal.
No. TE0001, Signosis, USA) according to the manufacturer’s
instruction. The DNA-binding activity of NF-κB was quantified
by EMSA as described previously (Hamid et al., 2009) using
EMSA assay kit (Catal. No. SIDET001, Viagene, China).
3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT)
Test
Upon completion of the 24 h reoxygenation, MTT assay was
performed to determine the viability of H9c2 cells in different
groups. Briefly, 50 µL exponentially growing cells (2 × 105
cells/mL) were seeded into a 96-well plate in triplicate. Then
5 mg/mL MTT was added to each well and incubated for 4 h at
37◦C. The OD values at 490 nm in different wells were recorded
using a Microplate Reader.
Immunofluorescent Microscopy
The nuclear translocation of NF-κB subunit p65 was detected
with immunofluorescent microscopy. Briefly, the treated cells
were seeded into 24-well chambers, washed with PBS, fixed
with 4% paraformaldehyde for 15 min. Then the cells were
permeabilized with 0.5% Triton X-100 for 30 min. After being
washed with PBS for three cycles, the cells were blocked
in 10% goat serum for 15 min. Primary rabbit polyclonal
antibodies (1:200) to NF-κB p65 was then added and the
cells were incubated overnight at 4◦C in 1% goat serum.
Staining was performed by incubating the cells with fluorescein
isothiocyanate secondary antibody for 1 h. After incubation with
the secondary antibody, cells were washed and then stained
with 4,6-diamino-2-phenyl indole (DAPI) for 5 min at room
temperature. After extensive washing with PBS, the slides were
fixed and imaged with the fluorescent microscopy at 400×
magnification.
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Western Blotting
The total proteins were extracted from ischemic penumbra
by using the Total Protein Extraction Kit according to the
manufacturer’s instructions (Catalog No. WLA019, Wanleibio,
China). Nuclear NF-κB subunit p65 was extracted using Nuclear
and Cytoplasm Protein Extraction kit (Catal. No. WLA020,
Wanleibio, China). β-actin and Histone H3 were used as internal
reference proteins. Concentrations of protein samples were
determined using the BCA method and western blotting was
performed as described previously with some modifications. For
short, an equal amount of proteins was subjected to 10% sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
After transferring the proteins onto polyvinylidene difluoride
(PVDF) membranes, the membranes were washed with TTBS
for 5 min and then incubated with skim milk powder solution
for 1 h. Primary antibody against NF-κB subunit p65 (1:500),
p-IκBα (1:500), IκBα (1:500), p-ERK (1:500), ERK (1:500), p-JNK
(1:500), JNK (1:500), p-p38 (1:500), p38 (1:500), β-actin (1:1000),
or Histone H3 (1:500) was added and the membranes were
incubated at 4◦C overnight. Following washing with TTBS, the
membranes were incubated with HRP-conjugated IgG secondary
antibodies (1:5000) for 45 min at 37◦C. After washing, the blots
were developed using Beyo ECL Plus reagent and scanned in
the Gel Imaging System. The relative expression levels of the
target proteins were calculated with Gel-Pro-Analyzer (Media
Cybernetics, USA).
Statistical Analysis
All the data were expressed in the form of mean ± SD. Multiple
comparisons were conducted by Duncan method using general
liner model with a significant level of 0.05. All the statistical
analysis and image manipulation were conducted using R
language version 3.2.1 (R Foundation for Statistical Computing).
RESULTS
Administration of GP Alleviated the
Impairments on the Cardiac Function
and Structure Induced by I/R Injury in
Rats
Detail data of LVESP, LVEDP, and FS detection was shown
in Table 1. I/R injury caused significant reduction of LVESP
and FS, but the value of LVEDP was increased post I/R injury
induction. Administration of GP significantly alleviated the
impairments on cardiac function due to I/R injury. For LVEDP
and LVESP, average levels in I/R + GPM and I/R + GPH groups
were significantly higher than those in I/R group (P < 0.05;
Table 1). For FS, significant difference was detected only between
I/R + GPH and I/R groups (P < 0.05; Table 1). Moreover, the
effect of GP on improving cardiac function was dose-dependent,
with GP at 200 mg/kg body weight exhibiting the most powerful
treatment effect.
To confirm the damage to cardiomyocytes due to I/R injury,
the levels of LDH and CK in serum samples were also assessed.
The statistically significant increases in the content of the two
indicators were observed in I/R group compared with sham
group (P < 0.05; Table 1). However, the levels of LDH and CK
in GP treated group were markedly decreased, suggesting the
potential of GP in protecting cardiac function against I/R injury.
As illustrated by H&E staining, severe damages were observed
in I/R group. However, pretreatment with GP obviously
ameliorated the damages in myocardial cells (Figure 1A).
As shown in Figure 1B, exposure to GP before I/R injury
dramatically decreased the infarction area (P < 0.05). However,
even for I/R + GPH group, the infarct area was still much larger
than that in sham group.
Administration of GP Increased the Cell
Viability in OGD/R Injured H9c2 Cells
As shown by MTT assay, OGD/R treatment significantly
decreased the cell viability of H9c2 cells compared with control
group (P < 0.05; Figure 2). Administration of GP at different
doses all enhanced the cell viability. Additionally, administration
of MAPK inhibitors also restored the cell viability of OGD/R
injured cells to a similar level of that in OGD/R + GPH group,
and no significant difference between the three MAPK inhibitors
was detected.
Administration of GP Inhibited the
Production and Nuclear Translocation of
NF-κB
The DNA binding activity of NF-κB was detected by EMSA.
I/R injury induced increase in NF-κB DNA binding activity
was significantly inhibited by GP treatment (P < 0.05,
Figure 3A). Moreover, the ELISA assay demonstrated that
TABLE 1 | Treatment with gypenoside (GP) improved the cardiac function in model animals (mean ± SD).
Parameters Group
Sham I/R I/R + GPL I/R + GPM I/R + GPH
LVESP (mmHg) 128.6 ± 6.8 79.0 ± 6.8a 81.3 ± 8.0a 93.1 ± 5.1ab 102.7 ± 9.0abc
LVEDP (mmHg) 6.0 ± 1.9 14.2 ± 3.5a 10.9 ± 4.7 8.8 ± 2.2b 7.8 ± 1.4b
FS (%) 48.3 ± 5.9 33.1 ± 6.3a 34.1 ± 4.0a 35.5 ± 5.6a 45.6 ± 6.0bc
LDH (U/L) 967.6 ± 276.5 2921.8 ± 983.8a 2208.0 ± 731.7a 1994.2 ± 519.1 1477.8 ± 350.4b
CK (U/mL) 1.2 ± 0.4 4.7 ± 1.2a 3.7 ± 1.5a 3.4 ± 1.2a 2.2 ± 0.5b
aSignificantly different from sham group, P < 0.05. bSignificantly different from I/R group, P < 0.05. cSignificantly different from I/R + GPL group, P < 0.05.
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FIGURE 1 | Administration of gypenoside (GP) alleviated the impairments in myocardial tissues due to I/R injury. (A) Illustration of hematoxylin and eosin
(H&E) staining of the myocardial tissues in different rats groups: the nuclei in myocardial tissue were stained blue and cytoplasm were stained red. Arrows indicating
the demolition of cell structure. Scale bar: 100 µm. (B) Treatment with GP significantly decrease the infarct area caused by I/R injury. a, significantly different from
sham group, P < 0.05. b, significantly different from I/R group, P < 0.05.
FIGURE 2 | Administration enhanced cell viability in OGD/R injured
H9c2 cells. a, significantly different from Control group, P < 0.05. b,
significantly different from OGD/R group, P < 0.05. c, significantly different
from sham group OGD/R + GPL group, P < 0.05.
I/R injury dramatically induced the expression of NF-κB.
Administration with GP could suppress the I/R injury-induced
NF-κB production (Figure 3B). The inhibiting effect of GP on
the activation of NF-κB was dose-dependent.
The changes in DNA-binding activity of NF-κB in H9c2 cells
were similar to those in in vivo experiments (Figure 3C). OGD/R
treatment induced the nuclear translocation of NF-κB and GP
administration inhibited the DNA-binding activity. Result of
ELISA based on H9c2 cells showed a similar pattern to that in
in vivo assay (Figure 3D). Once activated, NF-κB subunit p65
can be translocated into nuclei and bind to its target genes. Thus,
immunofluorescence was employed to detect the subcellular
localization of NF-κB p65 in H9c2 cells. As shown in Figure 4,
OGD/R treatment contributed to the nuclear translocation of
NF-κB p65 and pre-treatment with GP evidently inhibited the
translocation of p65 into nuclei in OGD/R cells.
Administration of GP Attenuated the
Activation of NF-κB via Inhibition of
MAPK Pathway
We found that I/R injury induced the translocation of p65 into
nuclei (Figure 5). Consistently, the phosphorylation levels of
IκBα, an indicator of NF-κB activation, were enhanced by I/R
injury, but the expression of IκBα was decreased by I/R injury
(Figure 5). These changes were reversed by GP administration.
To further evaluate the role of the upstream regulators of NF-
κB in the protection of GP against I/R injury, the expression
of ERK, p-ERK, JNK, p-JNK, p38, and p-p38 was detected. As
shown in Figure 5, the phosphorylation status of ERK, JNK,
and p38 were induced by I/R injury and pre-treatment with GP
inhibited the phosphorylation of the three indicators, suggesting
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FIGURE 3 | Treatment with GP significantly inhibited the production and nuclear translocation of NF-κB. (A) The graph represented the relative NF-κB
binding activity, and the image represented the EMSA results in I/R injured rats. (B) The graph represented the relative NF-κB binding activity, and the image
represented the EMSA results in OGD/R H9c2 cells. (C) The NF-κB activity was analyzed using a NF-κB p65 ELISA Kit, and value of OD450 represented the activity
of NF-κB p65 in I/R injured rats. (D) The NF-κB activity was analyzed using a NF-κB p65 ELISA Kit, and value of OD450 represented the activity of NF-κB p65 in
OGD/R H9c2 cells. a, significantly different from sham or Control group, P < 0.05. b, significantly different from I/R or OGD/R group, P < 0.05. c, significantly
different from sham group I/R + GPL or OGD/R + GPL group, P < 0.05. d, significantly different from OGD/R + GPM group, P < 0.05.
that GP may suppress the activation of NF-κB via inhibition of
phosphorylation of ERK, JNK, and p38.
Based on the results of in vivo experiments, western blotting
was conducted with three additional groups to further confirm
the effects of GP on MAPK mediated NF-κB activation in I/R
injured cardiomyocytes. The expression changes of indicators in
H9c2 cells were shown in Figure 6. The influence of I/R injury
on the expression of our targeted molecules was similar to those
in in vivo experiment and pre-treatment of GP also showed a
comparable effect to that in in vivo experiments. Additionally,
treatment with MAPK pathway inhibitors also attenuated the
changes in these molecules induced by OGD/R injury, indicating
that GP inhibits NF-κB activation by suppressing the MAPK
signaling transduction (Figure 6). But the protective effect of
GP on cardiomyocytes via MAPK pathway might be more
complicated as expected, our results showed that administration
with each MAPK inhibitor did not only inhibit the expression
of the specific target but also inhibited other MAPK members
in OGD/R models (Figure 6). In addition, all the three MAPK
inhibitors exhibited a similar effect on the activation of NF-κB
pathway (Figure 6), raising the possibility that the activation of
NF-κB by MAPKs might need the actions of multiple pathways.
DISCUSSION
Definitive therapy for myocardial ischemic disease always
depends on the perfusion process, but injury induced by
the reperfusion process has casted complex obstacles to the
effective treatment of ischemic disease (Ma et al., 2014). Hence,
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FIGURE 4 | GP suppressed the nuclear translocation of NF-κB p65 induced by OGD/R in H9c2 cells. Scale bar: 50 µm.
FIGURE 5 | Effect of GP treatment on the expression of molecules involved in the MAPK mediated NF-κB activation in I/R injured rats. a, significantly
different from sham group, P < 0.05. b, significantly different from I/R group, P < 0.05. c, significantly different from I/R + GPL group, P < 0.05.
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FIGURE 6 | Effect of GP treatment on the expression of molecules involved in the MAPK mediated NF-κB activation in OGD/R H9c2 cells.
a, significantly different from control group, P < 0.05. b, significantly different from OGD/R group, P < 0.05. c, significantly different from OGD/R + GPL group,
P < 0.05. d, significantly different from OGD/R + GPM group, P < 0.05. e, significantly different from OGD/R + GPH group, P < 0.05. f, significantly different from
OGD/R + U0126 group, P < 0.05. g, significantly different from OGD/R + SP600125 group, P < 0.05.
mechanism related to I/R injury has drawn a lot of attention and
become a critical subject of cardiovascular studies. Unfortunately,
even with plenty of effort being made to improve the myocardial
I/R injury recent years, little progress has been achieved. GP is
the predominant component of a traditional medicine in Asia.
The agent has been reported to have treatment effect on various
diseases (Feng et al., 2012; Qin et al., 2012; Zhao et al., 2014).
In the present study, GP was employed to ameliorate the I/R
injury in rat model and H9c2 cells. In in vivo experiments,
our data showed that values of LVESP, LVEDP, and FS were
improved by pre-treatment of GP. Moreover, the production
of indicators for necrotic damage and cardiomyocyte injury,
including LDH and CK, were measured and the results confirmed
protective effect of GP on cardiac function against I/R injury.
GP administration also alleviated the damage to cardiomyocyte
structure. Based on the results of H&E and TTC staining,
deterioration in cardiomyocytes and infarction in myocardial
tissues were reduced by precondition of GP.
As mentioned above, I/R injury is characterized by the release
of many cytokines and chemokines (Nakamura et al., 2000;
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Won et al., 2002; Ekshyyan and Aw, 2004; Xiao et al., 2008),
expressions of which always result in the activation of NF-κB
(Chung et al., 2012). The molecule regulates the expression of
variable immediate-early and stress response genes (Frantz et al.,
2007) and plays a decisive role in I/R injuries. Numerous studies
have assessed the potency of targeting NF-κB pathway as a
therapy for I/R injury prevention and treatment (Frantz et al.,
2007; Kim et al., 2009; Hamid et al., 2010; Ma et al., 2014). In
the current study, it was showed that GP pre-treatment could
reduce the phosphorylation level of IκBα as well as inhibiting the
translocation of NF-κB p65 to nuclei. Simultaneously, incubation
with GP also increased the content of IκBα in H9c2 cells, which
would contribute to the inhibition of NF-κB activity. It is widely
recognized that blockade of NF-κB pathway can lead to the
reduced release of pro-inflammatory cytokines and chemokines
(Onai et al., 2004; Kim et al., 2010; Gu et al., 2012; Ramachandran
et al., 2012). And disruption of NF-κB’s translocation in nuclei
will weaken the synthesis of monocyte chemoattractant protein-
1 (MCP-1) during chronic inflammation (Higa et al., 2012),
reduce the expression of IL-6 (Lee et al., 2013), and decrease
the secretion of MMP-2 and MMP-9 (Lu and Lai, 2013). This
regulated pattern of NF-κB pathway will contribute to the
resistance of cells to the degradation of the extracellular matrix
and inflammatory response. Combined with these studies, our
data evidently showed that GP had the capability to protect
cardiomyocytes against I/R injury through the inhibition of NF-
κB pathway.
The three members of MAPK pathway, ERK, JNK, and p38
are capable of initiating the activity of NF-κB (Ma et al., 2014). In
the current study, it was of interest to note that the ERK, JNK, and
p38 were all activated simultaneously in cardiomyocytes when
exposed to I/R manipulation. The temporal expression profile as
well as the extent of activation of the three MAPK members was
similar, suggesting that their activation is a common response of
the cardiomyocytes to I/R. However, the phosphorylation levels
of ERK and p38 in the present study were quite different from
that in Ma et al.’s (2014) study, in which the levels of p-ERK and
p-p38 did not change after ginsenoside Rb3 treatment. Ma et al.
(2014) had inferred that regulation of NF-κB was cell or tissue
specific and effect of natural products administration depended
on the cell sensitivity to the certain agent. Given that p-ERK
and p-p38 being down-regulated by GP in the present study,
GP should have a distinct mechanism in protecting myocytes
against I/R injury as compared with commonly recognized
ginsenoside Rb3.
To dissect the roles of the three indicators in I/R induced NF-
κB activation, U0126, SP600125, and SB203580 were employed
in in vitro assay. Based on the western blotting assay, it was
not surprising to find that the three inhibitors all suppressed
the expression of their specific targets in a similar pattern to
that of GP. However, the effect of each inhibitor had more
impact on its specific MAPK, it seemed that they also inhibited
other MAPKs. In the study of Yue et al. (2000) based on
cardiomyocytes I/R injury, MEK1/MEK2 inhibitor PD98059 at
50 µmol/L significantly enhanced the activity of p38 and JNK
while the effect of SB203580 on JNK varied with concentration.
Thus, some researchers concluded that the roles of ERK, JNK,
and p38 are cell type specific (Liu et al., 1996; Nemoto et al.,
1998). Taken the performance of the inhibitors in our study
into consideration, the cross talk between members of MAPK
pathway is extremely complicated. Even though the inhibitors
employed in the current study are highly specific, regulation
of one member in MAPK pathway will indirectly influence the
activity of other MAPKs.
Although numerous studies have reported that activation
of ERK, JNK, and p38 contribute to the up-regulation of
NF-κB pathway, few ones have provide a detail explanation
on the regulation scheme of NF-κB by MAPKs. Some
researchers infer that ERK, JNK, and p38 can increase the
phosphorylation of IKK-β which is responsible for IκBα
degradation and NF-κB nuclear translocation (Huang, 2008;
Yeh et al., 2011; Slomiany and Slomiany, 2013). Additionally,
other work with some insights into the subject indicates
that: ghrelin, a peptide hormone, is capable of suppressing
IKK-β in an anti-p38/JNK manner. However, the modulatory
effect of the agent is also associated with an enhancement
in ERK activity (Slomiany and Slomiany, 2013). Concatenated
with our finding that each MAPK inhibitor exhibited a
similar regulation pattern on NF-κB, it is hypothesized that
the activation of NF-κB may require involvement of the
three MAPKs at the same time. To test the hypothesis,
further work regarding the mechanism of GP in protecting
cardiomyocytes against I/R injury needs to be conducted in the
future.
CONCLUSION
The major findings outlined in the current study indicated
that GP regulated I/R injury via the following mechanism: (1)
GP contributed to the blockade of NF-κB p65 translocation
into nuclei, which would in turn inhibit NF-κB’s binding
to certain transcriptional region of pro-inflammatory factors.
(2) GP administration would decrease the phosphorylation
of IκBα and increase the level of IκBα in cardiomyocytes,
which would inhibit the activation of NF-κB as well. (3) GP
also exerted its function by inhibiting the expression of ERK,
JNK, and p38, which would negative regulate the activation
NF-κB. Our study evidently showed the potential of GP to
be a promising agent to prevent cardiomyocytes against I/R
injury. However, shortcomings still exist in the current study,
our experiments were designed to reveal the effect and to
preliminarily uncover the pathway through which GP takes
action on I/R injury, but we ignored to determine the suitable
practical dose or the effect of GP comparable to current treatment
modalities. To uncover the underlying mechanism involved in
the treatment effect of GP and facilitate the application of
the agent, more comprehensive work is being conducted in
our lab.
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